Comparative Pharmacology
Head-to-head clinical analysis: FYARRO versus TEMSIROLIMUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYARRO versus TEMSIROLIMUS.
FYARRO vs TEMSIROLIMUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYARRO (sirolimus protein-bound particles for injectable suspension) is an mTOR inhibitor. Sirolimus binds to FKBP-12 and inhibits mTOR complex 1 (mTORC1), reducing phosphorylation of downstream effectors such as S6K1 and 4E-BP1, thereby inhibiting cell growth, proliferation, and angiogenesis.
Temsirolimus is a specific inhibitor of mTOR (mammalian target of rapamycin) kinase. It binds to FKBP-12, and the Temsirolimus-FKBP-12 complex binds to and inhibits mTOR, thereby blocking the translation of cell cycle regulatory proteins (e.g., cyclin D1, c-myc) and hypoxia-inducible factor (HIF) subunits, leading to cell cycle arrest in G1 phase and antiangiogenic effects.
Recommended dose is 100 mg/m² (up to 200 mg maximum) administered as an intravenous infusion over 30 minutes once weekly on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
25 mg intravenously over 30-60 minutes once weekly.
None Documented
None Documented
Clinical Note
moderateTemsirolimus + Digoxin
"Temsirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemsirolimus + Digitoxin
"Temsirolimus may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemsirolimus + Deslanoside
"Temsirolimus may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTemsirolimus + Acetyldigitoxin
"Temsirolimus may decrease the cardiotoxic activities of Acetyldigitoxin."
Approximately 53 hours (terminal elimination half-life), supporting once-weekly IV administration.
17.3 hours in patients with advanced solid tumors; range 9-27 hours. Renal impairment (CrCl <30 mL/min) may prolong half-life. No dose adjustment needed for mild-moderate hepatic impairment.
Primarily via biliary/fecal excretion (approximately 77% of the dose recovered in feces as metabolites); renal excretion accounts for approximately 18%.
Primarily via feces (78%) and urine (4.6%) after IV administration; unchanged drug is minimal, with metabolites abundant.
Category C
Category D/X
mTOR Inhibitor
mTOR Inhibitor